The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move that signals a strategic shift in the cardiovascular drug market, Merck has received FDA approval for Lipfendra. This medication marks the first oral PCSK9 inhibitor to be taken once daily for adults struggling with high LDL cholesterol levels. According to reports, this innovation aims to provide a more convenient treatment option for patients who previously had to rely exclusively on injectable therapies.
This approval positions Merck strongly within the multi-billion dollar global cholesterol market, competing against injectable giants like Amgen's Repatha and Sanofi's Praluent. Per market data, the shift toward oral delivery provides Merck with a significant competitive edge due to improved patient adherence. Clinical data has previously suggested that oral PCSK9 inhibitors can achieve cholesterol reduction levels comparable to established biologic injections.
Shares of MRK closed at $127.63 (close July 16, 2026), after reaching an intraday high of $128.93. Investors are now looking forward to upcoming earnings calls to gauge the commercial rollout strategy for the new drug and its projected impact on top-line growth. In the broader macro context, traders continue to monitor U.S. inflation data to assess overall market sentiment toward the defensive healthcare sector.